Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Pharmacogenetics and genomics - 1 Jul 2013

Innocenti Federico, Ramírez Jacqueline, Obel Jennifer, Xiong Julia, Mirkov Snezana, Chiu Yi-Lin, Katz David A, Carr Robert A, Zhang Wei, Das Soma, Adjei Araba, Moyer Ann M, Chen Pei Xian, Krivoshik Andrew, Medina Diane, Gordon Gary B, Ratain Mark J, Sahelijo Leonardo, Weinshilboum Richard M, Fleming Gini F, Bhathena Anahita

Abstract excerpt

OBJECTIVE: ABT-751, a novel orally available antitubulin agent, is mainly eliminated as inactive glucuronide (ABT-751G) and sulfate (ABT-751S) conjugates. We performed a pharmacogenetic investigation of ABT-751 pharmacokinetics using in-vitro data to guide the selection of genes for genotyping in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arylsulfotransferase

Share to Gene Dosage

Share to Glucuronosyltransferase

Share to Sulfonamides

Share to Sulfotransferases

Share to Tubulin Modulators

Source

Open in PubMed Open full text

Identifiers

PMID: 23670235
DOI: 10.1097/FPC.0b013e3283623e81
PMCID: PMC3858967

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23670235-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.PMID 23670235Read ↗

Sulfotransferase genetic variation: from cancer risk to treatment response.Semantic proximity Read ↗

Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug DevelopmentSemantic proximity Read ↗

Sulfotransferase gene copy number variation: pharmacogenetics and function.Semantic proximity Read ↗

Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies.Semantic proximity Read ↗

Pre-Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta-Analysis and Recommendation.Semantic proximity Read ↗

Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.Semantic proximity Read ↗

Resequencing the sulfotransferase SULT1 gene provides new insights, while illuminating challenges that lie ahead for pharmacogenomics.Semantic proximity Read ↗

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.Semantic proximity Read ↗

Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity.Semantic proximity Read ↗

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.